March 17, 2025

Statins Reduce HCC Risk in Liver Disease

New research shows statin therapy significantly lowers hepatocellular carcinoma and hepatic decompensation risk while improving fibrosis outcomes in chronic liver disease patients with elevated FIB-4 scores.

Conexiant

March 14, 2025

Fungal Biomarkers Identified in Pulmonary Hypertension

A study in BMC Medicine identifies airway fungal shifts in pulmonary hypertension, highlighting potential diagnostic biomarkers.

Conexiant

March 14, 2025

Maternal Health Trajectories: CVD Risks Start Before Pregnancy

Women with adverse pregnancy outcomes had higher BMI, BP, and glucose 10 years before pregnancy and persistently elevated risks up to 15 years postpartum, a new cohort study finds.

Conexiant

March 14, 2025

Reduced-Dose Anticoagulants Lower Bleeding, Study Finds

Findings indicate that while non-inferiority was not established, the reduced-dose regimen resulted in fewer bleeding complications without a marked increase in venous thromboembolism (VTE) recurrence.

Conexiant

March 14, 2025

No Increased Cardiovascular Risk with Nicotinamide Use: Study

Analysis of over 13,000 patients across two cohorts found that nicotinamide exposure was not associated with increased risk of major adverse cardiovascular events

Conexiant

March 14, 2025

Colchicine Tied to Fewer CV Events in Gout

Patients with gout initiating urate-lowering therapy had a reduced risk of cardiovascular events when prescribed colchicine prophylaxis, researchers report.

Conexiant

March 14, 2025

Study Questions Prenatal Supplement Dose Guidelines

Current prenatal supplement doses may be set well below optimal levels, as a systematic review highlights gaps in efficacy and calls for reassessment of evidence-based recommendations.

Conexiant

March 13, 2025

Multivitamins After MI: Any Benefit for Patients with Diabetes?

The primary endpoint occurred in 35% of both the OMVM and placebo groups, according to a randomized trial evaluating multivitamins in post-MI patients with diabetes.

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters